Condition: Solid Tumor · Sponsor: Salubris Biotherapeutics Inc
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
This description comes directly from the study's public registry record.
Naimish Pandya, MD · +1-888-521-8961 · naimish.pandya@salubrisbio.com
Jennifer Lindelien · +1-888-521-8961 · jennifer.lindelien@salubrisbio.com
Always discuss trial participation with your own doctor first.
| Universitair Ziekenhuis Antwerpen | Antwerp, Belgium | Recruiting |
| Institut Jules Bordet | Brussels, Belgium | Recruiting |
| UZ Ghent | Ghent, Belgium | Recruiting |
| CHU UCL Namur - site Godinne | Yvoir, Belgium | Recruiting |
| NEXT Oncology Barcelona | Barcelona, Spain | Recruiting |
| START Barcelona | Barcelona, Spain | Recruiting |
| Vall d Hebron Institute of Oncology VHIO | Barcelona, Spain | Recruiting |
| CUN Madrid | Madrid, Spain | Recruiting |
| October 12th Hospital | Madrid, Spain | Recruiting |
| Next Oncology Madrid | Madrid, Spain | Recruiting |
| START Madrid | Madrid, Spain | Recruiting |
| CUN Pamplona | Pamplona, Spain | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06667960